

Mr. Bryan Thomas  
bryanjthomas1956@gmail.com

**SMDG selects the internationally renowned legal firm of Cooley LLP as its general counsel**

(Denver, CO, February 16, 2018) – SMDG (S.M. Discovery Group), a life sciences and bio-nanotechnology company that has developed a revolutionary nano-delivery system for unimpeded penetration of physiological barriers including the Blood-Brain Barrier, announced the addition of Cooley LLP as its primary outside counsel.

Cooley will be instrumental in helping SMDG through the next stage of further developing the technology platform and transition to IND application leading to other transactional events, according to Dr. Shadi Farhangrazi, SMDG CEO and co-founder. “We are delighted to have Cooley guide our team. Their expertise in biotech will help SMDG amplify its goals and objectives,” said Farhangrazi.

Cooley is considered the preeminent law firm in the tech and life sciences industry sectors representing more than 140 life sciences corporate partnering and licensing deals since 2000 with an aggregate value of \$38 billion. The firm represents 35% of the Wall Street Journal’s Billion Dollar Start-up list. It has facilitated over 1,000 M&A transactions aggregately valued at over \$340 billion since 2012. It has 13 offices across the United States, China and Europe with a worldwide staff of 2,000 including over 900 lawyers and 300 partners in a single-tier global partnership.

In its role as primary outside counsel, Cooley will be complementary to SMDG’s highly accomplished board of advisors including Dr. Moein Moghimi, SMDG Co-Founder and Senior Advisor, Professor of Pharmaceutics, Newcastle University, UK, and adjunct faculty at College of Pharmacy, University of Colorado Denver; Dr. A. Waseem Malick, world-

renowned for his work in pre-formulation, formulation, analytical and drug delivery research, having served as the Global Head of Pharmaceutical & Analytical R&D at Hoffmann-La Roche before recently retiring; Dr. Patrick Couvreur, Full Professor of Pharmacy at the Paris-Sud University and holder of the chair of “Innovation Technologique” (2009-2010) Collège de France, as well as Recipient of Europe’s Innovation Award; and Dr. Donald Tomalia, Director of the National Dendrimer and Nanotechnology Center and is considered one of the top 40 chemists in the world. Each member of the advisory board is recognized globally for their accomplishments, as well as is highly published within various industry and science community.

SMDG has developed a proprietary self-assembled nano-platform from a peptide ligand for “active(or receptor)-targeting” of physiological barriers. Based on industry “simple-and safe-by-design” standards and a decade of research from one of the top nanomedicine laboratories in Europe, its innovative, patent-protected platform is a versatile and multifunctional disruptive technology that overcomes specificity and target binding avidity limitations in “active-targeting” with particulate drug carriers. SMDG’s technology has proven to be highly efficacious in crossing biological barriers (including the Blood-Brain-Barrier) without inducing any toxicity effects.

---